Cargando…
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
BACKGROUND: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate...
Autores principales: | de la Piedra, C, Alcaraz, A, Bellmunt, J, Meseguer, C, Gómez-Caamano, A, Ribal, M J, Vázquez, F, Anido, U, Samper, P, Esteban, E, Álvarez-Ossorio, J L, Lara, P C, San José, L A, Contreras, J A, del Alba, A G, González-Gragera, B, Tabernero, A J, González-Enguita, C, Fernández, J M, García-Escudero, A, Gómez-Veiga, F, Méndez, M J, Segarra, J, Virizuela, J A, Carles, J, Lassa, A, Calderero, V, Constela, M, Delgado, D, Mañas, A, Murias, A, Reynes, G, Rodriguez, B, Rubio, G, Sánchez, E, Unda, M, Solsona, E, Martínez-Javaloyas, J M, Comet-Batlle, J, Quicios, C, Martín-Fernández, M, Mahillo-Fernández, I, Morote, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694249/ https://www.ncbi.nlm.nih.gov/pubmed/23722472 http://dx.doi.org/10.1038/bjc.2013.270 |
Ejemplares similares
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
por: Alcaraz, A, et al.
Publicado: (2013) -
SEOM Clinical Guideline for bone metastases from solid tumours (2016)
por: Grávalos, C., et al.
Publicado: (2016) -
Osteogenic preconditioning in perfusion bioreactors improves vascularization and bone formation by human bone marrow aspirates
por: Harvestine, J. N., et al.
Publicado: (2020) -
Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer
por: Orcajo-Rincon, J., et al.
Publicado: (2022) -
Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
por: Croes, M., et al.
Publicado: (2018)